GABA and PEA for HRV: Interesting Signals, Thin Evidence

Two supplements, one autonomic target

GABA and palmitoylethanolamide (PEA) look like an odd pairing. GABA is an inhibitory neurotransmitter; PEA is a lipid compound studied for anti-inflammatory and endocannabinoid-related effects. Yet two recent small randomized trials reported improvements in heart rate variability (HRV), a measure used to assess cardiac autonomic regulation.

That is worth examining because HRV is a legitimate physiological endpoint, not a wellness-app invention. Measures such as SDNN and frequency-domain indices reflect variation between heartbeats and can capture changes in parasympathetic, or vagal, modulation under standardized conditions. Lower HRV commonly accompanies stress and cardiometabolic risk, though one reading cannot diagnose health, resilience, or biological age. HRV changes with sleep, illness, caffeine, training load, breathing, and the time of day. The metric is useful; the marketing built around it is often less disciplined.

The two supplement studies point in the same direction, but neither establishes a dependable supplement strategy for improving autonomic health. The GABA study cannot separate its supplement result cleanly from a powerful exercise intervention. The PEA study has a better design for a small HRV experiment, but it remains an exploratory crossover study of 16 young women without biomarker evidence for its proposed mechanism.

What the GABA trial found—and what it cannot isolate

Guimarães et al. enrolled 30 sedentary Brazilian women with overweight and assigned them to 200 mg per day of oral GABA or placebo for 90 days. Both groups also completed supervised exercise throughout the study. The investigators reported statistically significant between-group effects favoring GABA, along with HRV changes consistent with greater parasympathetic predominance, better sleep efficiency, lower negative affect, and lower depression scores on the DASS-21.

The duration and placebo-controlled parallel design are reasonable features for an early supplement trial. Ninety days is longer than the quick, one-visit studies that dominate many HRV claims. The study also used established questionnaires and a physiologically relevant endpoint.

But the missing comparison matters more than those strengths. There was no exercise-only group. In this population, structured exercise is already a sufficient explanation for improved HRV, sleep, mood, and depressive symptoms. A systematic review and meta-analysis in sedentary people found that exercise training improves cardiac-parasympathetic activity. A separate review in postmenopausal women also reported exercise-related improvements in cardiovascular autonomic modulation.

Those reviews do not prove that GABA did nothing. The reported between-group difference could reflect an added effect. But exercise adherence, adaptation to supervised sessions, expectations, and measurement conditions can all complicate attribution in a 30-person trial. The published abstract also does not provide absolute HRV change values, so readers cannot judge the size of the reported difference.

The proposed brain-based mechanism has a second gap. Oral GABA would need to influence relevant autonomic pathways, yet the study did not report plasma concentrations, cerebrospinal-fluid levels, or blood-brain-barrier penetration at 200 mg per day. Whether supplemental oral GABA reaches central nervous system targets in humans at this dose remains unresolved. A pleasing mechanism diagram is not pharmacokinetics.

PEA produced a measurable SDNN change in a small crossover study

Deb et al. studied Levagen+, a proprietary PEA formulation, in 16 moderately stressed female university students in the United Kingdom. Participants had Perceived Stress Scale scores above 13, a body-mass index of 20 to 30, and a mean age of 22 plus or minus 2.4 years. In the six-week crossover trial, participants received 600 mg per day of PEA and placebo at different periods, allowing each participant to serve as her own control.

The reported HRV result was a 9.7 ms increase in SDNN versus placebo, alongside lower perceived stress. For a small study of a variable physiological measure, crossover is a sensible choice: comparing a participant with herself reduces between-person variation. The trial was preregistered as NCT06225440 and reported as CONSORT-compliant.

Still, a statistically reported change in SDNN does not automatically establish clinical importance. No minimum clinically important difference for a 9.7 ms SDNN increase in stressed women of this age was established here, and no confidence interval was supplied in the available summary. The study was an exploratory HRV sub-study rather than a trial powered primarily to characterize autonomic effects.

PEA has several plausible biological routes: activation of PPAR-alpha, effects on fatty-acid amide hydrolase that could alter endogenous anandamide signaling, and reduced mast-cell degranulation. None was measured. The trial collected no CRP or IL-6 data, no anandamide assays, and no FAAH activity measures. Its result therefore supports a hypothesis about PEA and autonomic function; it does not identify the pathway.

Why exercise sets the standard

The common target in both trials is biologically credible because autonomic regulation responds to behavior. Exercise benefits are not confined to healthy athletes. A 2024 meta-analysis in people with hypertension reported improved cardiac autonomic modulation with physical exercise, while a systematic review in type 2 diabetes found exercise training improved HRV.

Low-intensity approaches can matter as well. A 2024 systematic review and meta-analysis of Tai Chi reported HRV improvements, and the randomized crossover SED-ACT trial found that interrupting prolonged sitting with standing or walking conditions changed HRV parameters in young adults with overweight or obesity. These studies do not offer a direct millisecond benchmark for the PEA result, but they make autonomic change through movement biologically unsurprising.

Other inputs can affect the same system. In a preregistered factorial randomized trial of 120 healthy adults, Kamboj et al. tested transcutaneous vagus nerve stimulation with self-compassion imagery training and measured HRV among the outcomes. The vagal-autonomic axis can respond to more than exercise. That makes a supplement effect possible in principle, not demonstrated in practice.

Who should care, and how much?

Neither trial applies broadly. Both enrolled women only: sedentary women with overweight in the GABA study and stressed women in their early twenties in the PEA study. Hormonal status, baseline fitness, stress exposure, medication use, age, and sex can all affect autonomic measures and response to interventions. Neither result establishes benefit for men, older adults, athletes, or people with diagnosed cardiovascular or psychiatric disease.

Both studies were single-site and provide no evidence that an HRV change persists after supplementation stops. The PEA formulation is proprietary, and author conflict-of-interest status could not be verified from the available information. Publication venue alone cannot decide whether a result is valid, but independent replication matters especially when a small trial tests a branded product.

HRV is a credible target. The evidence for these two supplements is early, population-specific, and far weaker than the evidence for regular movement.

For GABA, the current study chiefly confirms what its exercise component was already expected to do: improve autonomic regulation and related well-being measures in previously sedentary women. A future trial needs an exercise-only arm and human pharmacokinetic evidence before anyone can credit 200 mg of oral GABA with an independent autonomic effect.

For PEA, the 9.7 ms SDNN result deserves replication in a larger, independently funded trial with prespecified HRV power calculations, mechanistic biomarkers, and a more diverse sample. Until then, PEA is an interesting signal, not a reason to replace the interventions that already have a deeper evidence base: exercise, less uninterrupted sitting, and stress-management practices people can actually sustain.